144 - mRNA Technologies and their Implications in Therapeutics: Q&A with Dr. Martin

HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast

Sean P. Kane, PharmD, BCPS

Health & Fitness, Medications, Rosalindfranklin, Rfums, Pharmacy, Pharmd, Pharmacist, Medicine, Drugs

5 • 644 Ratings

🗓️ 1 March 2022

⏱️ 28 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

In this episode, we interview Dr. Danyelle Martin, a Medical Science Liaison (MSL) at Moderna, in order to learn more about the what, how, and future of mRNA-based therapeutics, and what impact it can have on healthcare and healthcare professionals in general.

Key Concepts

Moderna has a “Research Engine” proprietary service that takes an mRNA idea from a web-based digital designer, to a digital ordering system, and finally to a production facility where mRNA constructs are synthesized and quality tested.
Pharmaceutics play a big role in the formulation of mRNA particles. Lipid nanoparticles (LNPs) play an important role for stability and delivery of mRNA cargo. After LNPs and mRNA are co-formulated, the product is purified, filtered, frozen, and subjected to a series of good manufacturing practice (GMP) tests to ensure product quality.
COVID-19 vaccines are a small glimpse into the potential future of mRNA-based therapeutics. Moderna’s pipeline includes mRNA vaccines for other viruses (including RSV, influenza, Zika and CMV) as well as therapeutics for non-viral diseases (including a personalized cancer vaccine and a VEGF-A mRNA molecule for myocardial ischemia).

Transcript

Click on a timestamp to play from that location

0:00.0	Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.
0:11.0	This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.
0:17.0	This podcast contains general information for educational purposes only. This is not professional
0:22.4	advice and should not be used in lieu of obtaining advice from a qualified health care provider.
0:27.2	And now, on to the show.
0:31.6	Hey, Helix Talk listeners. This is Dr. Kane. Before we get into today's episode, I want to let you
0:37.1	know that we originally recorded this with Dr. Martin on Before we get into today's episode, I want to let you know that we originally
0:38.1	recorded this with Dr. Martin on November 23, 2021. Since that time, several things have happened,
0:44.9	including Moderna's full FDA approval of Spike Vax, the MRNA COVID-19 vaccine. We don't
0:50.6	talk about that in the episode because we didn't know it at the time back in November, but I thought it was important that you, the listener, know that this was recorded several
0:57.4	months prior to an action being published on helixotoc.com.
1:00.9	And now, without further ado, on to the show.
1:05.2	Welcome to Helix Talk episode 144.
1:08.3	I'm your co-host, Dr. Kane.
1:10.0	And I'm Dr. Patal. And in today's episode,
1:13.1	we have a guest speaker to talk up-and-coming exciting thing. The title of our episode is
1:19.3	MRNA technologies and their implications in therapeutics, Q&A with Dr. Martin. So the sheer
1:26.2	mention of the word MRNA kind of brings in the light of the, you know,
1:30.4	COVID-19 vaccine in the market.
1:32.9	Dr. Kane, we have kind of recorded some COVID-19 related episodes recently.
1:38.1	But today's episode, we're not focusing on the vaccine so much.
1:43.1	We instead want to dive in the depths of the science,
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Sean P. Kane, PharmD, BCPS, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Sean P. Kane, PharmD, BCPS and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.